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Abstract: Excitotoxicity is the principle mechanism of acute injury during stroke. It is defined as the
unregulated accumulation of excitatory neurotransmitters such as glutamate within the extracellular
space, leading to over-activation of receptors, ionic disruption, cell swelling, cytotoxic Ca2+ elevation
and a feed-forward loop where membrane depolarisation evokes further neurotransmitter release.
Glutamate-mediated excitotoxicity is well documented in neurons and oligodendrocytes but drugs
targeting glutamate excitotoxicity have failed clinically which may be due to their inability to protect
astrocytes. Astrocytes make up ~50% of the brain volume and express high levels of P2 adenosine
triphosphate (ATP)-receptors which have excitotoxic potential, suggesting that glutamate and ATP
may mediate parallel excitotoxic cascades in neurons and astrocytes, respectively. Mono-cultures
of astrocytes expressed an array of P2X and P2Y receptors can produce large rises in [Ca2+]i;
mono-cultured neurons showed lower levels of functional P2 receptors. Using high-density 1:1
neuron:astrocyte co-cultures, ischemia (modelled as oxygen-glucose deprivation: OGD) evoked a rise
in extracellular ATP, while P2 blockers were highly protective of both cell types. GluR blockers were
only protective of neurons. Neither astrocyte nor neuronal mono-cultures showed significant ATP
release during OGD, showing that cell type interactions are required for ischemic release. P2 blockers
were also protective in normal-density co-cultures, while low doses of combined P2/GluR blockers
where highly protective. These results highlight the potential of combined P2/GluR block for
protection of neurons and glia.
Keywords: astrocyte; ATP; excitotoxicity; glutamate; NMDA; neuron; P-2 receptor; stroke
1. Introduction
Stroke involves the sudden onset of cerebral ischemia, producing cellular injury and loss of
function, leading to permanent disability [1,2]. The principle mechanism underlying acute cell
injury is excitotoxicity, involving the toxic build of extracellular neurotransmitters. Work towards
an effective prophylactic intervention for patients at stroke risk has focused on ionotropic glutamate
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receptors (GluRs) and the neuro-protective promise of blocking excitotoxic over-activation of
N-methyl-D-aspartate (NMDA)-type GluRs (see [3]). We have recently demonstrated, for example,
that many of the contraindications of this approach can be resolved by using a low-dose prophylactic
strategy employing the clinically approved drug memantine hydrochloride [4], and that selective
targeting of Nr2C/D NMDA subunits is highly protective of both grey and white matter. However,
~50% of the brain parenchymal volume is made of astrocytes, essential neural partner cells that are
required for neuronal survival and function. Astrocytes generally express low levels of GluRs (e.g., [5])
but robustly express P2 nucleotide adenosine triphosphate (ATP) receptors (see [6]). ATP can also act
as an excitotoxin via activation of P2 receptors [7,8] and extracellular ATP is significantly elevated both
in vitro and in vivo under hypoxic and ischemic conditions [9–16]. Prolonged application of ATP or
ATP analogues produces necrotic and delayed cell damage in both neurons and astrocytes in vitro and
in vivo [17–21]. The harmful effects of ATP may be enhanced during ischemia by a reduced efficiency
of ATP-degrading ecto-nucleotidases, which will reduce the capacity of the brain to clear extracellular
ATP [22,23].
Astrocytes play important roles in the acute injury and survival of neurons affected by ischemia,
including the release/uptake of neurotransmitters, regulation/dysregulation of extracellular ionic
homeostasis and the production/buffering of reactive species. In addition to their essential support
role in neural function, astrocyte cell death is a prerequisite for the evolution of necrotic stroke
infarction [24]. Astrocyte protection may also be directly beneficial to neighbouring neuronal elements;
for example, astrocyte glycogen storage can have a powerful influence upon the survival chances of
neighbouring axons [25]. In the present study, we use neuron-enriched, astrocyte-enriched and 50/50
co-cultures where the two cell types can be distinguished to probe the effects of P2 receptor block
on oxygen-glucose deprivation (OGD)-induced neurotransmitter release and associated cell death.
We report that, even at very low concentrations, P2 receptor block is a highly effective pathway to
astrocyte protection from acute ischemia which, unlike GluR block, reduces both neuron and glia
injury. Combined block of P2 and GluRs effectively prevented cell death, the first time a combined
pharmacological strategy has been identified to block acute ischemic cell death in both neurons
and glia.
2. Materials and Methods
2.1. Cell Culture
Normal-density primary cortical neuron and astrocyte co-cultures were prepared from the cerebral
cortices of C57BL/6 mouse gestation day 15–17 embryos (Charles river, Margate, UK), following
humane cervical dislocation under UK Home Office Schedule 1 regulations. Cortices were removed and
placed into Hank’s balanced salt solution (HBSS), trypsinised (1% trypsin/DNAse) at 37 ◦C for 10 min,
triturated and then centrifuged (1500 rpm/5 min). Cells were subsequently re-suspended in growth
media (Dulbeco’s minimum essential medium (DMEM), containing 4500 mg/L glucose, Glutamax-I,
110 mg/L pyruvate, penicillin/streptomycin and 10% foetal bovine serum (FBS)), and plated onto
175 cm2 flasks. At two days in vitro (DIV), excess microglia were removed by gentle tapping and
swirling of the flask prior to 100% DMEM media change. At six DIV, unwanted oligodendrocytes and
microglia were removed by multiple agitations and washing steps until the lower-most astrocyte layer
remained. Astrocytes were removed from the flask by trypsin action (0.5% Trypsin/5.3 mM EDTA),
centrifuged and re-suspended in DMEM. Astrocytes were counted and plated at 0.15 × 106 cells/mL
onto previously poly-L-lysine (100 µg/mL) coated coverslips. At eight DIV cortical neurons were
prepared from E16 embryos in the same fashion as astrocytes up to the initial re-suspension where
the media used was Neurobasal (Neurobasal medium, penicillin/streptomycin, B27 supplement,
Glutamax-I). Cells were passed through a 100 µm cell strainer prior to counting. Neurons were plated
at 0.15 × 106 cells/mL directly on top of previously plated astrocytes and the media was changed to
Neurobasal. Cultures were used from 12 DIV. High-density neuronal-enriched, astrocyte-enriched
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and 1:1 co-cultures were prepared from BALBc mice in a similar fashion to the above but using higher
plating densities (see [4] for details). These high-density cultures were useful for characterising receptor
responses and measuring neurotransmitter release.
2.2. Distinguishing Neurons and Astrocytes in Co-Culture
Co-cultured astrocytes and neurons are morphologically distinct under phase contrast.
To distinguish between the co-cultured cells, pseudo-fluorescent images were overlaid on the
corresponding phase-contrast images for identification. Astrocytes form a continuous layer of flat
low phase-contrast cells, whereas neuronal cells are high contrast showing pyramidal, fusiform or
multipolar characteristics; these identifying characteristics have recently been confirmed in sister
cultures [4]. Unidentifiable cells were excluded from subsequent analysis.
2.3. Cell Imaging (Viability and [Ca2+]i)
For imaging of cell viability, cell death was assessed using an intracellular green CellTrackerTM
probe, 5-chloromethylfluorescein diacetate (CMFDA) (Fisher, Loughborough, UK), AM loaded at
2.5 µM. CMFDA-loaded cultures were mounted into an atmosphere perfusion chamber (Warner
Instruments, Hamden, CT, USA), perfused at 2 mL/min (artificial cerebro-spinal fluid (aCSF) mM:
153 Na+, 3 K+, 2 Mg2+, 2 Ca2+, 131 Cl−, 26 HCO3−, 2 H2PO4− and 10 dextrose (bubbled with O2 95%/CO2
5%), 317–319 milliosmoles) and maintained at 37 ◦C. Temperature was monitored and regulated via
flow-through, objective and room heaters (see [26]). Once mounted onto the stage of an epi-fluorescence
microscope (Nikon, Tokyo, Japan), oil immersion×20 images were collected at 508 nm via appropriate
filter sets (Chroma Technology Corporation, Bellows Falls, VT, USA) following excitation at 489 nm
(optoscan, Cairn Research, Faversham, UK). Images were captured by a coolSNAP HQ camera (Roper
Scientific, Vianen, The Netherlands) controlled via MetaFluor (Molecular Devices, San Jose, CA, USA)
with background signal subtracted. OGD conditions were induced by switching from aCSF to aCSF-zero
glucose (OGD mM: 153 Na+, 3 K+, 2 Mg2+, 2 Ca2+, 131 Cl−, 26 HCO3−, 2 H2PO4− (bubbled with N2
95%/CO2 5%) and switching the chamber atmosphere from 95% O2/5%CO2 to 95%N2/5%CO2. Cultures
were perfused with aCSF for 10 min before switching to OGD. Two sets of image data were collected
from each CMFDA experiment. Quadrant images were taken at 0 and 100 min of perfusion where initial
cell and surviving cell counts were taken in the four complete adjacent fields of view contiguous with
the imaged field in the centre. These quadrant images were used to determine total cell death over the
whole time-course of the experiment, and also acted as a control to ensure that fluorescent excitation
illumination was not affecting cell viability (these cells were not exposed to illumination during the course
of the experiment). Fluorescent images were taken every 30 s from the central field of view where cell
death was characterised by a sudden collapse of the fluorescent signal as previously described (see [4]).
These data were used to calculate cell death rates with time within the field of view. Cell death data are
plotted as a time course represent the real time recordings from the central field of view, while total cell
death data include the cells from the surrounding quadrants.
For [Ca2+]i imaging during OGD, cultures were loaded with FURA-2FF (Invitrogen, Carlsbad,
CA, USA), a low affinity dye that does not affect cell viability during ischemia [27]. The more sensitive
FURA-2 was used for agonist responses. In both cases, cells were AM-loaded (see [26] for more details
of imaging methods). A rapid exchange perfusion system was used for short application agonist
experiments (ValveBank8.2, AutoMate Scientific, Berkeley, CA, USA). Oil immersion ×20 images were
collected at 520 nm using appropriate filter sets (Chroma Technology Corporation, Bellows Falls, VT,
USA). Cells were illuminated at 340, 360, and 380 nm (Optoscan, Cairn Research, Faversham, UK).
For FURA-2 imaging, 340:380 was converted to [Ca2+]i using a calcium calibration kit (Invitrogen).
Cell death was characterized by sudden collapse of the fluorescent signal to the background level and
this phenomenon was used to calculate cell death rates and precise time points of cell death for all
cells within the field of view.
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2.4. Biosensors
ATP and glutamate microelectrode biosensors (Sarissa Biomedical, Coventry, UK) [28], amplified
via a Duo-Stat ME-200+ potentiostat (Sycopel International Ltd., Tyne & Wear, UK), were used to record
real time glutamate or ATP concentration changes in vitro from the unstirred fluid layer surrounding
cells in high-density cultures. Signals were recorded differential to a null electrode and both active
and null electrodes were carefully inserted into a modified atmosphere chamber until the sensor tips
rested directly on the cell layer (see [4]). An Ag/AgCl reference electrode was introduced at a distal
site. OGD and control experiments were performed as described above for cell imaging. Sensors
were recalibrated in the chamber at the end of the OGD period after retraction from the cell layer.
Values from the null, sensor, and sensor-minus-null outputs were recorded at 0.5 Hz and subsequently
converted into ∆ ATP or ∆ glutamate, rather than absolute concentrations. Experiments were repeated
a minimum of three times, all values collected for a time point during a specific condition/experiment
were averaged using Prism software (GraphPad, Prism Software, Droitwich, UK).
2.5. Statistics
Experiments were repeated a minimum of three times on three separate culture preparations.
Results are presented as mean ± standard error of the mean (SEM). Statistical analysis for comparison
of experimental groups was undertaken using one-way analysis of variance (ANOVA) with Tukey’s
post-hoc test for multiple comparisons. For all data, differences of p < 0.05 were deemed significant.
3. Results
3.1. Functional P2 Receptors and GluR in Astrocyte-Enriched and Neuron-Enriched Cultures
Functional GluR and P2 ATP receptor expression was examined in neuron- and astrocyte-enriched
cultures, using Ca2+ micro-fluorimetry. Resting [Ca2+]i was significantly higher in astrocyte cultures
compared to neurons (98.0 nM ± 3.0 n = 554 vs. 65.0 nM ± 1.5, n = 739, respectively; p < 0.001), and
in both cases was affected by tonic application of various receptor antagonists used in this study.
For this reason, [Ca2+]i changes have been used for the statistical comparison of drug effects, rather
than absolute [Ca2+]i levels. To confirm the presence of functional P2 receptors on astrocytes, cells were
exposed to a series of P2 receptor agonists. One hundred percent of astrocytes responded to 100 µM
ATP, with a mean [Ca2+]i increase of 722.9 ± 29.2 nM (n = 341; Figure 1A–C). All receptor sub-type
selective agonists tested (100 µM adenosine diphosphate (ADP), 100 µM ATPγS, 10 nM MRS-2365,
100 µM BzATP) had response rates approaching 100% and produced smaller [Ca2+]i responses than
those produced by ATP, in the 328–539 nM range (Figure 1A–C). A second application of 100 µM ATP
at the end of the experiment produced a [Ca2+]i rise of a similar amplitude to the initial response, but a
degree of response run-down was found during multiple sequential applications of ATP (falling to
84.9% of the first response after six repeats, 5 min apart, n = 62). Small amplitude glutamate responses
were observed in a sub-set of cultured astrocytes (e.g., Figure 1A), as reported in a companion study [4].
The presence of ionotropic glutamate receptors is well documented in cultured neurons (see [4]
for studies on sister cultures), P2 receptor responses less so. The proportion of cells in neuronal cultures
responding to sequential exposure to a series of P2 agonists ranged from 58.0 ± 4.2% for ATP down to
26.4 ± 7.1% for BzATP (Figure 1D,E), in all cases significantly lower than the corresponding response
rate in astrocyte cultures. The maximal [Ca2+]i rises evoked by P2 agonists were also smaller than
in astrocytes, between 110.0 ± 4.6 nM for ATP and 56.9 ± 4.3 nM for BzATP (Figure 1F). In general,
neurons responded to either the majority of P2 agonists or none at all, although the amplitude of
responses varied within cells. As with astrocytes, a degree of hysteresis in the ATP response was
observed in cultured neurons with a second application evoking a significantly smaller response
(Figure 1F).
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Figure 1. P2 receptor-mediated responses in astrocyte and neuronal cultures. (A) [Ca2+]i recorded from
a typical individual astrocyte showing baseline and agonist-evoked responses. Raw pseudo-colour
images from this experiment are shown at the top, demonstrating cell responses to each of the agonists
(each colder spot in the resting image is a single cell). Scale = 10 µm. (B) Mean number of astrocytes
which respond to individual agonists (n = number of individual cultures). (C) Mean change in [Ca2+]i
evoked by agonists (n = individual astrocytes). (D–F) Similar series to (A–C), in this case for cultured
neurons. ATP: adenosine triphosphate, ADP: adenosine diphosphate.
Since neurons express both functional GluR and P2 receptors, the effects of combined P2 + GluR
block were examined on agonist-induced responses in neuronal cultures. Combined block of GluR and
P2 receptors (60 min pre-treatment with 30 µM NBQX + 10 µM MK-801 + 100 µM PPADS) reduced the
proportion of neurons responding to glutamate (under zero-Mg2+ conditions) from 100% to 72.0± 3.2%,
with response amplitude falling by 73.1% (p < 0.001; n = 107; Figure 2A–D). Responses to specific
NMDA- and non-NMDA-type ionotropic glutamate receptor agonists were suppressed to a greater
extent than those to glutamate, indicating a significant metabotropic component to the glutamate
response in cultured neurons. The cellular ATP response rate fell to 13.7 ± 6.6% (p < 0.001; n = 231) in
the presence of the antagonist cocktail, but the amplitude of [Ca2+]i rises in the remaining responding
cells was not significantly affected (Figure 2C,D).
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Figure 2. Combined P2 and ionotropic glutamate receptor block of neuronal responses. (A,B) [Ca2+]i
changes evoked by serial application of the receptor agonists glutamate (100 µM), AMPA (100 µM),
NMDA (100 µM) + glycine (10 µM) and ATP (100 µM) in two cultured neurons from the same culture
in the combined presence of 30 µM NBQX + 10 µM MK-801 + 100 µM PPADS (pre-applied for 60 min,
all in zero-Mg2+). These two cells show the range of responses observed. Note that, while all responses
are small or blocked in the cell shown in (A), robust glutamate and ATP responses are retained in (B).
(C,D) Mean number of responding cells (C) and mean [Ca2+]i changes (D).
Astrocytes express a wide range of P2 receptors and to differentiate P2X- and P2Y-mediated
responses the Ca2+-dependence of P2 responses in these cells was investigated [29]. Astrocyte cultures
were pre-treated with 1 µM thapsigargin for 60 min to block sarcoplasmic/endoplasmic reticulum
Ca2+-ATPase (SERCA) and deplete Ca2+ stores prior to sequential exposure to ATP and ADP in the
presence and then the absence of extracellular Ca2+ (Figure 3). In normal aCSF, thapsigargin treatment
reduced the proportion of ATP-responding cells from 100% to 60.1 ± 13.0% and response amplitude to
7.3% of control (both p < 0.001). All responses were eliminated by the removal of extracellular Ca2+
(Figure 3B,C). The data suggest that ~60% of astrocytes express functional P2X receptors but that these
contribute less than 10% to the Ca2+ rises evoked by ATP. ADP, which is a selective agonist for a sub-set
of P2Y receptors, produced only limited responses following thapsigargin treatment, consistent with
this hypothesis. The P2Y receptor compliment on astrocytes included a significant P2Y1 component
since ~30% of the [Ca2+]i response to ATP was lost when experiments were conducted on astrocyte
cultures prepared from P2Y1 −/−mice (Figure 4). The [Ca2+]i responses to ADP were also reduced
in these cells (by over 80%), and all effects of the selective P2Y1 agonist MRS-2365 were abolished
(Figure 4). As a corollary, this experiment demonstrates the purity of the ATP used since some cells
responded to ATP but not ADP; ADP impurity has been a major concern in commercially available
ATP [30].
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Figure 3. P2X and P2Y receptors are expressed in cultured astrocytes. (A) Representative data showing
the effects of 100 µM ATP and 100 µM ADP perfusion following depletion of Ca2+i stores by treatment
with 1 µM thapsigargin in the presence and then the absence of extracellular Ca2+. (B,C) Mean number
of responding cells (n = cover slips) (B) and mean [Ca2+]i changes (n = cells responding) (C) showing
the major contribution to ATP responses by P2Y receptors in these cells.
In astrocyte cultures, pre-incubation for 60 min with the broad-spectrum P2 antagonists suramin
(100 µM, Figure 5A,B) or PPADS (100 µM, Figure 5C,D) reduced the mean [Ca2+]i response to ATP
by 43.9 ± 1.4% and 55.9 ± 1.8% of control, respectively. ADP responses, which should be largely
P2Y-mediated, were reduced by 59.5 ± 1.9% and 39.5 ± 1.9%, respectively. Drug washout was
incomplete over the time-course of the experiment. Neither drug significantly reduced the 100%
response rate of the cells to either agonist. The concentration-dependence of PPADS was investigated
during shorter exposure periods (Figure 5E,F). Sixty-minute pre-incubation with combined application
of the selective P2Y1 antagonist MRS-2179 and the P2X7 antagonist KN-62 was also tested (Figure 5G,H).
This protocol significantly reduced the amplitude of the [Ca2+]i responses to ATP to 69.4 ± 2.2% of
control (p < 0.001, n = 119), with limited reversibility after 5 min wash-out. Somewhat larger effects of
this antagonist combination was found upon the responses evoked by the selective P2Y1 and P2X7
agonists MRS-2365 and BzATP (Figure 5G,H).
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Figure 4. P2Y1 receptors in astrocytes. (A,B) Representative responses in two astrocytes in cultures
prepared from P2Y1 −/− mice. (C,D) Mean number of responding cells (n = cover slips) (C) and mean
[Ca2+]i changes (n = cells responding) (D) showing lower amplitude [Ca2+]i rises in response to ATP
and ADP in the knock-out cells, and no response to the selective agonist MRS-2365.
Figure 5. P2 receptor block in cultured astrocytes. (A–D) The effect of pre-perfusion for 60 min with 100 µM
suramin or 100 µM PPADS upon ATP and ADP evoked [Ca2+]i changes. (E,F) Concentration-dependence
of the effect of PPADS during shorter antagonist exposures. (G,H) The effect of combined exposure to
the selective P2Y1 antagonist 10 µM MRS-2179 and the P2X7 antagonist 1 µM KN-62 upon ATP-evoked
[Ca2+]i changes.
3.2. Oxygen-Glucose Deprivation in High-Density Neuron/Astrocyte Co-Cultures
Ischemic conditions in the brain were modelled by exposing high-density co-cultures to OGD
with a similar neuron:astrocyte ratio to that found in the CNS (1:1). OGD evoked a gradual rise in
extracellular ATP measured in the unstirred media layer surrounding cells [4] (Figure 6A,B). The mean
extracellular ATP increase reached 8.9 ± 3.1 µM during the 80–90 min period of OGD (p < 0.01
relative to control perfused cultures). A significant elevation in ATP concentration was apparent in
the 60–70 min epoch (p < 0.05), but the data trend suggests that ATP release started soon after the
initiation of OGD (Figure 6A). Activation of P2 receptors during OGD was subsequently found to
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contribute to acute cell death in this preparation (See below). To test the hypothesis that P2 receptor
antagonists act independently of glutamate release, glutamate was measured in the mixed high density
cultures during OGD in the presence and absence of 10 µM PPADS (Figure 6C,D). OGD evoked an
early increase in extracellular glutamate in this preparation, and this was not significantly affected by
block of P2 receptors.
The effect of a range of ionotropic glutamate and P2 receptor blockers in isolation and in
combination (see Tables 1 and 2 for selectivity of P2 antagonists) were tested upon the degree of cell
death produced by 90 min of OGD in high-density co-cultures, assessed via CFMDA cell-tracker
imaging (Figure 7). This approach allowed neurons and astrocytes to be differentiated using
unambiguous morphological criteria [4]. The non-selective P2 antagonist PPADS (10 µM) was highly
protective of both neurons and astrocytes, with neuronal death reduced to 2.8 ± 1.7% and astrocyte
death to 9.4 ± 4.5% (n = 10; p < 0.001); PPADS (100 µM) (sufficient to block all P2 receptor types)
reduced total cell death to a level below that found in control perfused cultures (0.9 ± 0.5%; p < 0.001).
Suramin (100 µM) has been reported to block P2X 2, 3, 5, 6 and 7 in addition to P2Y 1, 2, 6, 12 and
13 types, produced significant protection of neurons but not astrocytes, reducing over-all cell death as
a result. In contrast, reactive blue-2, which at the concentration used (100 µM) has been reported to
block P2X 1–3 and 5 and P2Y 1, 4, 6 and 11–12, was without effect. The P2X7 selective antagonist KN-62
(1 µM) did not have a significant effect upon either cell type, while the P2Y1 antagonist MRS-2179
(10 µM) significantly protected both astrocytes and neurons from cell death, and reduced total cell
death to 15.5 ± 6.3%. Consistent with prior reports, block of non-NMDA or NMDA GluRs (NBQX
30 µM or MK-801 10 µM, respectively), was protective of neurons. The most significant protection
was found during combined application of both antagonists; no glutamate receptor blocking protocol
had any significant effect upon astrocyte survival. Combined block of P2 and glutamate receptors
with 100 µM suramin + 10 µM MK-801 + 30 µM NBQX (100S10M30N) completely abolished all cell
death in both astrocytes and neurons. Combined perfusion with low agonist concentrations was also
tested. PPADS (1 µM) + mk-801 (1 µM) + NBQX (1P1M3N) (3 µM) was highly protective of both
neurons (1.1 ± 0.9% cell death) and astrocytes (8.5 ± 3.9% cell death), with total cell death reduced
from 13.2 ± 1.6% to 5.0 ± 2.9% (p < 0.001).
Figure 6. Neurotransmitter release from mixed cultures. (A) ATP concentration in the media
surrounding cultured neurons and astrocytes rises gradually during a 90 min period of OGD (red data)
compared to control recordings (green). Means +/− standard error mean are shown. (B) Mean data
for each 10 min interval showing statistical significant between control and OGD at later time points.
(C) Glutamate in the extracellular media is elevated during OGD, an effect that is not affected by
co-perfusion with 10 µM PPADS to block P2 receptors. (D) Mean data for 10 min intervals, showing no
statistical significant effect of PPADS.
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Table 1. Antagonists at P2X receptors.
Suramin PPADS KN-62 Highly SelectiveAntagonists a,h,p,s
P2X1
No, >1 mM g (mouse) 0.4 g (mouse)
No NF449, NF864, RO-10.01–0.3, 0.851 e,t (human) 0.01–0.3, 1.29 a,t (human)
P2X2
33.1 e (rat) 3.8 e (rat)
No -1-32 m,p,t (human) 0.4–20.4 a,m,p,t (human)
P2X3
0.776 e (rat) 3.63 e (rat)
No -14.9, 15.8, >100 e,n,p,t (human) 1.7–5.13 e,n,t (human)
P2X4
>100 q (mouse) 10.5 q (mouse)
No, >3 q (mouse) Benzofuro-1,4-diazepin-2-ones178.1–200 e,o,p (human) 10–25,27.5, >100 a,o,p (human)
P2X5
4.5 r (rat) 2 r (rat)
No -0.199 p,t (human) 0.01-0.3, 3.16 p,t (human)
P2X6 No, >30 r (rat)
No, >30 r (rat)
>0.3 t (human) No -
P2X7 40 f (mouse)No, >100 e,t (human)
Cation pore opening Cation pore opening 1A-438079 **
14.79 a (mouse) 0.389 a (mouse) 1A-740003 **
3.24 a (human) 0.38 a (human) A-804590
Large pore formation Large pore formation GSK314181A
7, 9, >100 a,b (mouse) 0.18, 1.17 a,b (mouse) AZ11645373
0.015 b (human) 0.011 b (human) 1AZ10606120




16.6 a (human) RO-3
P2X1/5 1.58 p (rat) 0.5–8.6 h (mouse) No -
P2X4/6 Some activity u (rat) Some activity u (rat) No -
Numbers represent IC50 values, in µM. Murine data are presented where available. **: antagonists with good
oral bioavailability. References: a (Donnelly-Roberts et al., 2009), b (Chessell et al., 1998), e (Bianchi et al., 1999),
f (Watano et al., 2002), g (Ikeda, 2007), h (Lalo et al., 2008), m (Lynch et al., 1999), n (Garcia-Guzman et al., 1997a),
o (Garcia-Guzman et al., 1997b), p (Gever et al., 2006), q (Jones et al., 2000), r (Collo et al., 1996), s (Jarvis and Khakh,
2009), t (Burnstock and Knight, 2004), u (Le et al., 1998a).
Table 2. Antagonists at P2Y receptors.
Suramin PPADS MRS-2179 Highly SelectiveAntagonists h
P2Y1





















15 o (human) No
a,s,u MRS-2577
P2Y6
Effective at 100uM d
(mouse)
Effective at 30uM d
(mouse)
No a,s,u MRS-2578MRS-2575





P2Y13 2.3 e (human) 11.7 e (human) >100 e (human) MRS-2211
Numbers represent IC50 values, in µM; Murine data are presented where available. References: a (Fischer and
Krugel, 2007), b (Donnelly-Roberts et al., 2009), d (Calvert et al., 2004), e (Marteau et al., 2003), f (Baurand et al.,
2001), g (Atterbury-Thomas et al., 2008), h (Jacobson et al., 2009), n (Suarez-Huerta et al., 2001), o (Communi et al., 1996b),
p (Waldo and Harden, 2004), q (Moro et al., 1998), r (Abbracchio et al., 2006), t (Charlton et al., 1996b), u (Boyer et al., 1998).
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Figure 7. The effects of various receptor agonists on OGD-induced cell death in mixed cultures. (A) The per
cent cell death of all cells (blue), astrocytes (green) and neurons (red) under control perfused (white), control
OGD (black) and OGD in the presence of single or combined receptor antagonist (coloured). (B) Analysis
showing the mean time to the first cell death event in each culture. (C) Mean time to cell death. * p < 0.05, **
p < 0.005, *** p < 0.001 vs. cell death under control OGD conditions. “1P” = 1 µM PPADS; “1M” = 1 µM
MK-801; “3N” = 3 µM NBQX; “100S” = 100 µM suramin; “n” = number of cultures.
3.3. Oxygen-Glucose Deprivation in Normal-Density Neuron/Astrocyte Co-Cultures
To test whether the highly protective nature of combined P2 and GluR block was limited to the
high-density cultures required for biosensor recording of neurotransmitter release, we examined the
effect of combined blockade in normal density 50:50 neuron:astrocyte cultures using low doses of
clinically applicable drugs. Control levels of total cell death was higher in these normal-density cultures,
an effect that was countered by low concentrations of PPADS which acted by reducing astrocyte death
(Figure 8A). PPADS at 0.5 µM reduced total cell death under control normoxic conditions from
13.2 ± 1.6% to 3.1 ± 0.5% over the 100 min recording protocol (p < 0.001), suggesting tonic ATP
release and low levels of on-going P2 receptor-mediated excitotoxicity in these cultures. Ninety-minute
OGD evoked a significantly lower level of overall cell death (22.0 ± 1.6%; Figure 8B) than it did in
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the high density cultures (see Figure 7), the difference accounted for by a reduced level of astrocyte
death. This phenomenon is potentially related to lower levels of ischemic neurotransmitter release
associated with lower cell density. Very low levels of PPADS significantly reduced OGD-induced
astrocyte and total cell death, with 0.5 µM reducing overall cell death during OGD to 16.7 ± 5.8%
(p < 0.02 vs. OGD alone). PPADS (1 µM) reduced total cell death to 11.2± 1.6% (p = 0.01), with only the
highest concentration tested (10 µM) having any protective effect upon neurons (8.4 ± 2.2%, p = 0.002).
The time-course of cell death under control perfused and during OGD are shown in Figure 8C,D.
Figure 8. The effects of P2 and GluR antagonists on OGD-induced cell death in normal-density
co-cultures. (A) The extent of cell death during a 100 min period of control imaging, showing neuron,
astrocyte and neuron death. Note the relatively high level of baseline cell death in the absence of
antagonists and the protective effect of even low concentrations of PPADS or combined low dose PPADS
+ memantine. (B) Cell death during 90 min of OGD and the protective effects of low concentrations of
PPADS or low dose PPADS + memantine. (C–F) The time-course of total cell death for the two sets of
conditions shown in “A” and “B”. * p < 0.05, ** p < 0.005, *** p < 0.001 vs. no drugs present.
To test combined block of NMDA-type GluR and P2 receptors in this preparation, cultures
were exposed to 0.2 µM memantine + 0.5 µM PPADS. Current and established data show that these
concentrations given individually are not protective of total cell death in this preparation [4]. Following
application of this combination a significant protective effect against astrocyte (7.0 ± 2.0%, p < 0.0001)
and total cell death (7.0 ± 2.0%, p < 0.0001; Figure 8B) was found. However, no significant effect
was seen upon neuronal death (13.3 ± 2.4%, p = 0.0772). Memantine (0.2 µM) + PPADS (0.5 µM)
significantly decreased cumulative cell death at 75 min onwards compared to OGD-only conditions
(Figure 8F; p < 0.001). A further low concentration combination was investigated. PPADS (0.25 µM)
and MEM (0.1 µM) significantly reduced neuronal death (11.3 ± 3.0%; p < 0.01), with no effect on
astrocyte or all cell death (Figure 8D). This combination showed an increased cumulative level of cell
death in continually-imaged cells compared to OGD-only conditions (Figure 8F).
4. Discussion
The focus for acute stroke intervention research has been on re-vascularization therapies, reactive
species buffering or excitotoxicity interruption via NMDA-type GluR blockers [31]. Drugs directed
toward glutamate-mediated excitotoxicity have shown particular promise in animals, but have not
translated into clinical practice. Neural function is dependent upon the homeostatic relationship
between neurons and astrocytes, and any successful stroke intervention must protect both cell
types if functional improvement is to be achieved. Since the NMDA-type GluRs which largely
mediate glutamate excitotoxicity are either absent or expressed at low levels in astrocytes (e.g., [5]),
one shortfall of targeting glutamate excitotoxicity may be a lack of astrocyte protection. Astrocytes
express a high density of P2 ATP receptors [6], and brain ischemia produces significant rises in
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extracellular ATP concentration [16]; targeting ATP-mediated excitotoxicity may therefore be necessary
for stroke neuroprotection.
For ATP and glutamate mediated excitotoxic cascades to co-exist, cells must release excessive
ATP and glutamate during ischaemic conditions, events which we have confirmed in high-density
cultures using biosensor microelectrodes. Neurotransmitter release was apparent soon after the onset
of OGD, although ATP levels were lower and reached statistical significance later than glutamate.
In this preparation, astrocytes rather than neurons contributed the majority of glutamate release
during OGD, since significant glutamate release only occurred from astrocyte cultures and co-cultures.
Glutamate release from co-cultures was not attenuated by the non-selective P2 blocker PPADS,
suggesting that P2 receptor activation does not contribute to ischaemic glutamate release. Excessive
ischemic ATP release was only consistently detected in co-cultures, indicating that astrocytes and
neurons interact/co-operate by an unknown mechanism to release ATP or enhance extracellular ATP
accumulation during ischaemia.
A second pre-requisite for ATP and glutamate mediated excitotoxicity is the functional expression
of P2 and GluRs on neural cells. Functional receptor responses were examined via Ca2+ imaging,
revealing widespread ionotropic and metabotropic GluR responses in neuronal cultures, while only a
small percentage of cultured astrocytes expressed functional (mostly metabotropic) GluRs. Cultured
neurons and astrocytes expressed a variety of functional P2 receptors, with 100% of astrocytes and
approximately 60% of neurons responding to ATP. In both cell types, there was a dominant contribution
of metabotropic P2Y over ionotropic P2X receptors. A P2 receptor subtype expression profile obtained
using multiple P2 agonists/antagonists and P2Y1−/− astrocytes found expression on neurons and
astrocytes of P2Y1 and P2Y6, with a possibility of P2Y2 and/or P2Y4, while astrocytes in particular
also expressed functional P2X7 receptors.
4.1. GluR Antagonists Protect Neurons but Not Astrocytes
Blocking NMDA and/or AMPA/kainate GluRs reduced OGD-induced cell death in neurons
but not astrocytes. A similar differential effect has been previously documented in cell cultures, and
correlates with the largely neuronal pattern of GluR expression [4,32–35]. Analysis of the time course
of cell lysis revealed that the reduction in neuronal death produced by the NMDA blocker MK-801
reached statistical significance after 90 min of OGD, and did not reduce the mean time to cell death.
NBQX (alone or in combination with MK-801) significantly reduced cell death after 60–65 min of
OGD, and significantly delayed the mean time to cell death. Consistent with this, NMDA GluR
antagonists are less effective than AMPA/kainate receptor antagonists during prolonged and/or more
severe ischaemia.
4.2. Broad-Spectrum P2 Antagonists Protect Neurons and Astrocytes
Of the broad-spectrum P2 antagonists tested, PPADS is selective for P2 receptors while suramin
and RB-2 have non-specific effects including activity at GluRs [36–43] (see Tables 1 and 2). RB-2 did not
significantly affect cell death, although it did delay the mean time to cell death of all cells combined.
Suramin significantly reduced neuronal but not astrocyte death, and also increased the average time to
first death of neurons. PPADS was the most protective of the antagonists tested, significantly reducing
death of both neurons and astrocytes. PPADS (100 µM) almost eliminated cell death during the 90 min
OGD period, while 10 µM reduced astrocyte and neuron death by ~80% and significantly delaying the
average time to first death and mean time to cell death for both cell types.
Suramin or PPADS reduce neuronal death in primary neuron and brain slice cultures exposed
to glucose deprivation or OGD (injury assessed ≥ 20 h) [44–46]; protection with low (PPADS, 5 µM)
concentrations of has been reported in hippocampal slice cultures [47]. The current findings are the
first to demonstrate that P2 antagonists can protect neurons during acute ischaemia, and that PPADS
protects both neurons and astrocytes. The absence of protection afforded by RB-2 in the current results
contradicts reports that have measured injury at delayed time-points [45,48,49], and may indicate an
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effect of this blocker only on delayed injury. The selective P2X7 antagonist KN-62 also produced no
significant protection in high-density cultures, consistent with results with other P2X7 antagonist and
receptor knock-out animals where infarct volume following middle cerebral artery occlusion is not
significantly affected [50,51]. The size of excitotoxic lesions induced by the NMDA receptor agonist
methano-glutamate in vivo are not reduced in P2X7 −/− animals or by three different selective P2X7
antagonists, suggesting that these receptors are not involved in glutamate neurotoxicity [50,51].
P2Y1 receptor block was highly protective in high-density cultures. P2Y1 receptor block
delays anoxic depolarization in hippocampal slices [52], but the current data are consistent with
reports that P2Y1 block is effective against ischemic injury in vivo [53–55]. P2Y1 receptor activation
stimulates glutamate release from cultured hippocampal and spinal cord astrocytes but not neurons,
while P2Y1 receptor antagonists reduce ATP induced glutamate release from astrocytes [56–58].
P2Y1 antagonists may therefore act to mitigate glutamate excitotoxicity via reduced glutamate
release, although the current finding that PPADS did not reduce ischaemic glutamate efflux from the
co-culture argues against this. Furthermore, glutamate receptor antagonists only significantly reduced
neuronal ischaemic death without protecting astrocytes. Heteromeric functional coupling of P2Y1
and A1 receptors has been demonstrated in neurons and astrocytes [59,60], resulting in A1 receptor
desensitization following P2Y1 activation. Since A1 receptor activation is protective, P2Y1 blockers
may afford neural protection via this alternative mechanism. However, the most likely mechanisms is
reduced Ca2+ over-loading during OGD following receptor block; P2Y1 receptors are shown to mediate
a significant component of the Ca2+-rise evoked by ATP and since elevated [Ca2+]i is central to acute
ischemic cell injury, block of any receptor mediating [Ca2+]i elevation is predicted to be protective.
The data relating to receptor-mediated excitotoxic injury during acute ischemic conditions in mixed
neuron-astrocyte environments are summarized in Figure 9.
Figure 9. A model of purinergic and glutamatergic events involved in astrocyte and neuronal death
during OGD. Glutamate and ATP accumulate in the extracellular space following the onset of OGD:
glutamate is released by astrocytes, while the source of ATP is not clear. Glutamate evokes neuronal
death by gating AMPA/kainate and NMDA receptors, leading to cytotoxic Ca2+ influx. ATP activates
P2 receptors on both astrocytes and neurons, leading to Ca2+ release from intracellular stores (P2Y
receptors) and/or Ca2+ influx through P2X ion channels. P2Y1 receptors in particular are present on
both cell types and contribute to cell death. P2X7 receptors may be involved in early neuronal but not
astrocyte death.
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4.3. Synergistic Effect of P2 and Glutamate Receptor Antagonists
Initially, suramin (100 µM) + NBQX (30 µM) + MK-801 (10 µM) were added to high-density
cultures: this combination completely prevented cell death during 90 min of OGD and was significantly
more protective than either suramin or NBQX + MK-801 paradigms. To further probe this synergism,
PPADS (1 µM) + NBQX (3 µM) + MK-801 (1 µM) was tested. This combination, less likely to
produce non-selective effects, reduced acute astrocyte and neuron lysis by 83% and 95%, respectively,
and significantly delaying the onset and mean time to cell death more than any other antagonist
combination. The synergistic effect was significantly greater than that produced by either class of
antagonist alone, even when applied at high concentrations. A similar combined protective effect
was suggested in a study by Runden-Pran and colleagues [47], where the combination of suramin
(200 µM) + MK-801 (100 µM) significantly attenuated cell death in hippocampal slice cultures exposed
to 32 min OGD followed by up to 48 h of re-oxygenation [47]. However, this was not significantly
more protection than either antagonist on its own, and this suramin concentration is poorly specificity.
Low concentrations of PPADS or PPADS + the clinically approved NMDA GluR blocker memantine
were tested in normal density co-cultures. PPADS at 1 µM and combined 0.5 µM PPADS + 0.2 µM
memantine were protective against acute OGD-induced lysis in neurons and astrocytes, and also
reduced background levels of cell death in these cultures. The current data are the first to confirm
that a combinatorial approach blocking P2 and ionotropic glutamate receptors provides synergistic
protection against ischaemic death of astrocytes and neurons in vitro. Thus, a combinatorial approach
may be relevant to test in vivo but this will require the development of selective PPADS antagonists
which are able to cross the blood brain barrier.
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